Where do you go to find the very best growth stories?  Clearly, some of the best innovators come from the tech and the health-care industries. And so, almost by default, most of my Fast-Track Millionaire portfolio stocks belong to those two major growth sectors.  But what about the rest of the economy? Does it not generate any innovation or significant profit opportunities?  Of course, it does. And that’s what today’s piece is all about… —Recommended Link— This “Guaranteed Income Strategy” Is Batting .905 Since 2013, one income investment has been knocking it out of the park. In… Read More

Where do you go to find the very best growth stories?  Clearly, some of the best innovators come from the tech and the health-care industries. And so, almost by default, most of my Fast-Track Millionaire portfolio stocks belong to those two major growth sectors.  But what about the rest of the economy? Does it not generate any innovation or significant profit opportunities?  Of course, it does. And that’s what today’s piece is all about… —Recommended Link— This “Guaranteed Income Strategy” Is Batting .905 Since 2013, one income investment has been knocking it out of the park. In fact, the “Guaranteed Income Strategy” has banked 191 winners out of 211 trades — generating a $140,490 windfall. If collecting instant cash and winning 90.5% of the time sounds good to you, then grab the details on how you can pocket your first instant cash this Wednesday. To illustrate my point, look no further than a company like Tesla (Nasdaq: TSLA). Believe it or not, Tesla is an industrial company by any official classification. And regardless what you may think of the recent, well-publicized missteps of CEO Elon Musk, is indeed an innovator. And what’s more,… Read More

Despite choppy oil prices, master limited partnership (MLP) Magellan Midstream (NYSE: MMP) has managed to produce record distributable cash flows (DCFs) over the past year.  But that’s not altogether surprising, considering 90% of the firm’s income is fee-based, leaving just 10% sensitive to commodity prices. It’s also why we’ve held it in our portfolio over at The Daily Paycheck since 2010. Magellan At A Glance For those who are unfamiliar, Magellan owns 9,700 miles of refined products pipelines that connect with roughly half of the nation’s refineries. It also operates 53 terminals that have 45 million barrels of… Read More

Despite choppy oil prices, master limited partnership (MLP) Magellan Midstream (NYSE: MMP) has managed to produce record distributable cash flows (DCFs) over the past year.  But that’s not altogether surprising, considering 90% of the firm’s income is fee-based, leaving just 10% sensitive to commodity prices. It’s also why we’ve held it in our portfolio over at The Daily Paycheck since 2010. Magellan At A Glance For those who are unfamiliar, Magellan owns 9,700 miles of refined products pipelines that connect with roughly half of the nation’s refineries. It also operates 53 terminals that have 45 million barrels of gas and diesel fuel storage capacity. That’s in addition to 2,200 miles of crude oil pipelines that feed storage systems from the Gulf Coast to the nation’s main hub in Cushing, Oklahoma. Magellan doesn’t take possession of any oil or other liquids — it just gets paid for storage and transportation services. That compensation comes in the form of tariffs and fees (often under long-term contracts) based on the volume of oil and refined products flowing through its networks. #-ad_banner-#What’s New With MMP Thanks in part to a 4.4% tariff increase at mid-year, the company delivered record DCF of… Read More

You know you’ve stumbled across something good when other financial publishing outlets begin using it.  It is a bit of a catch-22, however, because on the one hand it’s an idea that we here at StreetAuthority developed and made popular, but don’t get credit for… On the other hand, imitation is the sincerest form of flattery. To be sure, it’s not as if we developed an iPhone model that every other competitor began mimicking, or some other ground-breaking technology. We simply came up with giving a sound, time-tested way of investing, a couple of catchy phrases. They aren’t proprietary, trademarked… Read More

You know you’ve stumbled across something good when other financial publishing outlets begin using it.  It is a bit of a catch-22, however, because on the one hand it’s an idea that we here at StreetAuthority developed and made popular, but don’t get credit for… On the other hand, imitation is the sincerest form of flattery. To be sure, it’s not as if we developed an iPhone model that every other competitor began mimicking, or some other ground-breaking technology. We simply came up with giving a sound, time-tested way of investing, a couple of catchy phrases. They aren’t proprietary, trademarked or patented. Nor should they be. But now, whenever I come across them on the Web, I simply smile and know that the history behind these popular headlines and marketing commentary all started here. You see, we’ve published thousands of in-depth research reports. Everything from high-dividend payers, game-changing innovations, top tech stocks, best plays in emerging markets — you name it, we’ve told you how to profit from it. But there are two pieces of research that have spread like wildfire since we first began publishing them over a decade ago. In fact, I hardly even mention or use the… Read More

Once again, an old-school company fails to keep up. Or just fails. General Electric (NYSE: GE), which just a month or so ago seemed to be out of the woods after two years of declining earnings and dividend cuts, just warned investors of another year of lower profits and forecasted that its industrial operations — formerly its bread and butter — could be up to $2 billion cash-flow negative this year. Just a month ago, the market was cheering GE’s decision to sell one of its important assets, the company’s biopharma unit, to Danaher (NYSE: DHR) for $21.4 billion. The… Read More

Once again, an old-school company fails to keep up. Or just fails. General Electric (NYSE: GE), which just a month or so ago seemed to be out of the woods after two years of declining earnings and dividend cuts, just warned investors of another year of lower profits and forecasted that its industrial operations — formerly its bread and butter — could be up to $2 billion cash-flow negative this year. Just a month ago, the market was cheering GE’s decision to sell one of its important assets, the company’s biopharma unit, to Danaher (NYSE: DHR) for $21.4 billion. The deal is expected to close in the fourth quarter. But the proceeds won’t be reinvested in the business. Rather, the proceeds will be used to reduce GE’s enormous debt. At year-end, GE had $108 billion in debt (almost as much as it had taken in revenue during the entire year, which was $121.6 billion). ​ The decision to reduce debt is the right one. The size of a company’s debt matters, especially when business suddenly slows. Too much debt can often lead to bankruptcy — even in a strong economy like ours today, let alone in leaner times. But when… Read More

Retail and institutional investors aren’t the only ones who used the fourth-quarter selloff last year as a buying opportunity.  Bristol-Myers Squibb (NYSE: BMY), one of the largest U.S. pharma companies by revenue, didn’t waste any time scooping up biotech Celgene (Nasdaq: CELG). Announced on January 3, the $74 billion acquisition is the second-largest pharmaceutical M&A deal ever (after the $87 billion merger of Warner-Lambert and Pfizer (NYSE: PFE) twenty years ago). Despite the price tag, it was still a bargain. Even though BMY offered a 53.7% premium to CELG’s closing price on January 2, the latter, which lost $30 per… Read More

Retail and institutional investors aren’t the only ones who used the fourth-quarter selloff last year as a buying opportunity.  Bristol-Myers Squibb (NYSE: BMY), one of the largest U.S. pharma companies by revenue, didn’t waste any time scooping up biotech Celgene (Nasdaq: CELG). Announced on January 3, the $74 billion acquisition is the second-largest pharmaceutical M&A deal ever (after the $87 billion merger of Warner-Lambert and Pfizer (NYSE: PFE) twenty years ago). Despite the price tag, it was still a bargain. Even though BMY offered a 53.7% premium to CELG’s closing price on January 2, the latter, which lost $30 per share between August 30, 2018, and year-end, still trades below its 52-week high. This price action shows how unexpected the deal was, and how little of the future M&A premium was “baked” into the price of CELG before BMY has made its move. Identifying potential M&A targets is a difficult process, but it can be worth the effort. After all, a jump of 30%, 50% or even more is a nice payoff… But it’s never wise to simply invest in a stock on the hopes that it will one day be acquired — hence the research part.  —Recommended Link— 9… Read More

Many traders ignore seasonal patterns, simply because they’re based on the calendar.  But I’m here to tell you that seasonal trends are important, and there’s a particular one that I want to highlight this week.  To find a seasonal trend, an analyst calculates how prices performed on a certain day in the past. For example, we know that since 1950, March has been an “up” month for the S&P 500 64% of the time. Since there’s normally about a 59% chance of an “up” month, that’s a slight seasonal bias to the “up” side.  However, that’s not really a tradable… Read More

Many traders ignore seasonal patterns, simply because they’re based on the calendar.  But I’m here to tell you that seasonal trends are important, and there’s a particular one that I want to highlight this week.  To find a seasonal trend, an analyst calculates how prices performed on a certain day in the past. For example, we know that since 1950, March has been an “up” month for the S&P 500 64% of the time. Since there’s normally about a 59% chance of an “up” month, that’s a slight seasonal bias to the “up” side.  However, that’s not really a tradable seasonal pattern because it doesn’t offer a very strong signal. An example of a strong signal would be one that tells us there is a 75% chance for a market gain in the next week, or if the probability of a gain in the next week is significantly below average.  …which is exactly what the charts are showing us right now.  For the next two weeks, seasonals are weak and that tells us to expect a pullback in the broad stock market.  There are several ways to look at seasonals. Two of the more popular techniques are shown below in… Read More